Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Cohen

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Lupus|December 17, 2021
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)Xin Wang, Elena Gkrouzman, Danieli Castro Oliveira Andrade, et al.
Advances in Rheumatology (London, England)|October 29, 2021
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryErivelton de Azevedo Lopes, Gustavo Guimarães Moreira Balbi, Maria G Tektonidou, et al.
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
Research and Practice in Thrombosis and Haemostasis|August 14, 2024
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trialPrabal Mittal, Rafael Gafoor, Zara Sayar, et al.
Lupus|July 25, 2020
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION RegistryStéphane Zuily, Isabelle Clerc-Urmès, Cédric Bauman, et al.
Rheumatology (Oxford, England)|October 18, 2024
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 2, 2023
Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and RepositoryYu Zuo, Sherwin Navaz, Alex Tsodikov, et al.
Lancet (London, England)|November 4, 2024
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trialDavid J Werring, Hakim-Moulay Dehbi, Norin Ahmed, et al.
Rheumatology (Oxford, England)|June 12, 2023
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registryGustavo G M Balbi, Yasaman Ahmadzadeh, Maria G Tektonidou, et al.
Stroke|April 1, 2026
Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled TrialJames Lyon, Philip S Nash, Norin Ahmed, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Lupus|December 17, 2021
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)Xin Wang, Elena Gkrouzman, Danieli Castro Oliveira Andrade, et al.
Advances in Rheumatology (London, England)|October 29, 2021
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryErivelton de Azevedo Lopes, Gustavo Guimarães Moreira Balbi, Maria G Tektonidou, et al.
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
Research and Practice in Thrombosis and Haemostasis|August 14, 2024
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trialPrabal Mittal, Rafael Gafoor, Zara Sayar, et al.
Lupus|July 25, 2020
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION RegistryStéphane Zuily, Isabelle Clerc-Urmès, Cédric Bauman, et al.
Rheumatology (Oxford, England)|October 18, 2024
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 2, 2023
Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and RepositoryYu Zuo, Sherwin Navaz, Alex Tsodikov, et al.
Lancet (London, England)|November 4, 2024
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trialDavid J Werring, Hakim-Moulay Dehbi, Norin Ahmed, et al.
Rheumatology (Oxford, England)|June 12, 2023
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registryGustavo G M Balbi, Yasaman Ahmadzadeh, Maria G Tektonidou, et al.
Stroke|April 1, 2026
Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled TrialJames Lyon, Philip S Nash, Norin Ahmed, et al.
Pageof 18